Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a Chemo-Radio duo slow advanced prostate cancer?

NCT ID NCT00126230

Disease control Sponsor: Gustave Roussy, Cancer Campus, Grand Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 19, 2026 · Last updated Aug 20, 2026 · Updated 1 time

Summary

This trial is testing whether combining the chemotherapy drug docetaxel with a radioactive agent called samarium can help men with advanced prostate cancer that has stopped responding to hormone therapy. Participants are men aged 18 to 80 who have bone metastases and whose disease has progressed despite hormone treatment, but who have not yet had chemotherapy. The study aims to see how long the cancer stays under control and whether the treatment is safe and tolerable.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
docetaxel and samarium (a chemotherapy drug combined with a radioactive agent)
What this could lead to
If effective, this combination could offer a new way to slow advanced prostate cancer that has stopped responding to hormone therapy.
What could go wrong
This is an early-phase trial with a small number of patients, so results may not hold up in larger studies. The treatment may cause side effects like low blood counts or kidney issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

55 people

Start date

Jan 2004

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients older than 18 years and less than 80 years * Histologically-proven adenocarcinoma of the prostate * Evidence of bone metastases and progressive, hormone-refractory, disease * No previous chemotherapy * No previous radiotherapy, except radiotherapy directed to the prostate and/or to a single bony lesion * No previous carcinoma, except basal-cell carcinoma of the skin * Adequate renal function: measured or calculated creatinine clearance \> 60 ml/min * Absolute granulocyte count ≥ 1,500/mm3, platelets ≥ 100,000 mm3, bilirubin ≤ 1.5 fold the upper normal value * Signed informed consent. Exclusion Criteria: * Patients infected by the Human Immunodeficiency Virus (HIV) * Patients who do not fit inclusion criteria

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hormone-refractory advanced prostate cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hormone-resistant prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Prostate cancer

Contacts and locations

Locations

  • Institut Gustave Roussy

    Villejuif, 94805, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.